GGrantIndex
← Leaderboards

Edus Houston Warren

Fred Hutchinson Cancer Center

$15,290,791
Attributed
$22,676,147
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.9M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,676,147 · 10

By mechanism

R01$9,296,612 · 4
U01$8,518,125 · 2
D43$2,246,918 · 2
P01$2,182,394 · 1
R21$432,098 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Center

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsT-LymphocyteTumorMalignant NeoplasmsUgandaCd8b1 GeneImmuneResponseInsightKaposi SarcomaGenesImmune ResponsePersonsHiv InfectionsAntiretroviral TherapyT Cell ResponseMediatingMorbidity - Disease RateNeoplastic CellAdultInstitutesAids Related CancerAntigensClinical Trials

Grant awards (41)

Comprehensive Characterization of the T-cell Response to KSHV to Enable Specific Immune Therapy$4,234,248
U01 · FY2025 · CA · contact PI
HIV persistence and treatment response in Kaposi sarcoma$432,098
R21 · FY2025 · CA · contact PI
Training in Cancer Genomics and Genomic Data Science$230,816
D43 · FY2025 · CA · contact PI
Cancer Genomics and Genomic Data Science for East Africa$1
D43 · FY2024 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$547,525
R01 · FY2023 · CA
Building independent research leaders in HIV-associated malignancies in Uganda$298,787
D43 · FY2023 · TW
Cancer Genomics and Genomic Data Science for East Africa$268,960
D43 · FY2023 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$634,763
R01 · FY2022 · CA
Building independent research leaders in HIV-associated malignancies in Uganda$299,012
D43 · FY2022 · TW
Cancer Genomics and Genomic Data Science for East Africa$269,160
D43 · FY2022 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$637,815
R01 · FY2021 · CA
Building independent research leaders in HIV-associated malignancies in Uganda$299,988
D43 · FY2021 · TW
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$218,186
R01 · FY2021 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$190,771
R01 · FY2021 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$175,086
R01 · FY2021 · CA
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$637,486
R01 · FY2020 · CA
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$417,390
R01 · FY2020 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$298,884
D43 · FY2020 · TW
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$658,549
R01 · FY2019 · CA
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$598,405
R01 · FY2019 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$281,310
D43 · FY2019 · TW
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$723,817
R01 · FY2018 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$644,421
R01 · FY2017 · CA · contact PI
Profiling cancer neoantigen repertoires and validating immunotherapy targets$1,064,486
U01 · FY2016 · CA
Profiling cancer neoantigen repertoires and validating immunotherapy targets$1,069,555
U01 · FY2015 · CA
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$414,751
R01 · FY2015 · HL
Profiling cancer neoantigen repertoires and validating immunotherapy targets$1,047,882
U01 · FY2014 · CA
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$412,570
R01 · FY2014 · HL
Profiling cancer neoantigen repertoires and validating immunotherapy targets$1,101,954
U01 · FY2013 · CA
H-Y-Specific T Cell Responses in Chronic GvHD$453,346
P01 · FY2013 · AI · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$399,948
R01 · FY2013 · HL
H-Y-Specific T Cell Responses in Chronic GvHD$482,293
P01 · FY2012 · AI · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$435,773
R01 · FY2012 · HL
H-Y-Specific T Cell Responses in Chronic GvHD$413,518
P01 · FY2011 · AI · contact PI
H-Y-Specific T Cell Responses in Chronic GvHD$420,560
P01 · FY2010 · AI · contact PI
H-Y-Specific T Cell Responses in Chronic GvHD$412,677
P01 · FY2009 · AI · contact PI
Allogeneic T Cell Responses Against Renal Cell Carcinoma$302,644
R01 · FY2008 · CA · contact PI
Allogeneic T Cell Responses Against Renal Cell Carcinoma$302,644
R01 · FY2007 · CA · contact PI
Allogeneic T Cell Responses Against Renal Cell Carcinoma$311,684
R01 · FY2006 · CA · contact PI
Allogeneic T Cell Responses Against Renal Cell Carcinoma$319,185
R01 · FY2005 · CA
Allogeneic T Cell Responses Against Renal Cell Carcinoma$313,199
R01 · FY2004 · CA